Aerovate Therapeutics Inc [AVTE] stock is trading at $1.66, down -0.60%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AVTE shares have gain 6.41% over the last week, with a monthly amount drifted -90.24%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aerovate Therapeutics Inc [NASDAQ: AVTE] stock has seen the most recent analyst activity on June 18, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $2 from $35. Previously, TD Cowen downgraded its rating to Hold on June 18, 2024. On June 18, 2024, downgrade downgraded it’s rating to In-line and revised its price target to $2 on the stock. Wedbush downgraded its rating to a Neutral and decreased its price target to $3 on June 17, 2024. Guggenheim downgraded its rating to a Neutral. BTIG Research downgraded its rating to Neutral for this stock on June 17, 2024.
Aerovate Therapeutics Inc [AVTE] stock has fluctuated between $1.25 and $32.42 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Aerovate Therapeutics Inc [NASDAQ: AVTE] shares were valued at $1.66 at the most recent close of the market. An investor can expect a potential return of 683.13% based on the average AVTE price forecast.
Analyzing the AVTE fundamentals
Gross Profit Margin for this corporation currently stands at 0.24% with Operating Profit Margin at -649.91%, Pretax Profit Margin comes in at -603.9%, and Net Profit Margin reading is -604.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -0.7 and Total Capital is -0.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5433 points at the first support level, and at 1.4267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7533, and for the 2nd resistance point, it is at 1.8467.
Ratios To Look Out For
For context, Aerovate Therapeutics Inc’s Current Ratio is 6.65. In addition, the Quick Ratio stands at 6.65 and the Cash Ratio stands at 0.59.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Jun 17 ’24 when 0.93 million shares were purchased., Eldridge George A completed a deal on Jun 14 ’24 to sell 15000.0 shares. Meanwhile, CHIEF TECHNICAL OFFICER Verwijs Marinus sold 10600.0 shares on Jun 14 ’24.
